Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 601–700 of 1,001
Sequential RAAS Blockade: Is It Worth the Risk?
Persson, F., & Rossing, P. R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.003 · Cited by 13
Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved
Gesualdo, L., & Paolo, S. D. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu372 · Cited by 13
A review of chemical therapies for treating diabetic hypertension
Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 16
Lessey, G., Stavropoulos, K., & Papademetriou, V. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s203925 · Cited by 15
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Nefrología · doi:10.1016/j.nefro.2021.10.003 · Cited by 16
Treatment of diabetic kidney disease. A network meta-analysis
Büttner, F., Barbosa, C. V., Lang, H., Tian, Z., Melk, A., & Schmidt, B. M. W. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293183 · Cited by 14
Jiang, X., Zhou, S., Yao, J., Kong, X., & Cui, M. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0240-y · Cited by 13
Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., PASSMAN, R. S., Pecoits‐Filho, R., Reinecke, H., Shroff, G. R., et al. (2019) · Nephrology (Saint-Petersburg) · doi:10.24884/1561-6274-2019-23-2-18-40 · Cited by 14
Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice
Yang, S., Chen, Y., Duan, Y., Ma, C., Liu, L., Li, Q., Yang, J. A., Li, X., Zhao, B., Wang, Y., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109389 · Cited by 13
Ye, H., Huo, Z., Ye, P., Xiao, G., Zhang, Z., Xie, C., & Kong, Y. (2020) · PeerJ · doi:10.7717/peerj.8575 · Cited by 13
The Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy
Bolignano, D., Pisano, A., & Coppolino, G. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1550017 · Cited by 14
Management of chronic kidney disease
Tomson, C., & Taylor, D. M. (2015) · Medicine · doi:10.1016/j.mpmed.2015.05.004 · Cited by 13
Effect of Losartan and Spironolactone on Triglyceride-Rich Lipoproteins in Diabetic Nephropathy
Srivastava, A., ADAMS-HUET, B. A., Vega, G. L., & Toto, R. D. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000102 · Cited by 14
Combined angiotensin inhibition in diabetic nephropathy.
Fried, L. F., Emanuele, N., & Zhang, J. H. (2014) · PubMed · doi:10.1056/nejmc1315504 · Cited by 6
Self-citationWebb, D. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae140 · Cited by 11
Miyasako, K., Maeoka, Y., & Masaki, T. (2024) · Biomedicines · doi:10.3390/biomedicines13010053 · Cited by 16
Urinary biomarkers of diabetic kidney disease
Gembillo, G., Soraci, L., Messina, R., Cicero, L. L., Spadaro, G., Cuzzola, F., Calderone, M., Ricca, M. F., Piazza, S. D., Sudano, F., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i1.110502 · Cited by 20
Acute kidney injury: quoi de neuf?
Reichel, R. R. (2014) · Europe PMC (PubMed Central) · Cited by 15
Preventing the development and progression of diabetic kidney disease: Where do we stand?
Zagkotsis, G., Markou, M. I., Paschou, E., Papanikolaou, P., & Sabanis, N. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.012 · Cited by 14
Hsieh, W., Chang, T.-H., Chang, H.-F., Chuang, W.-H., Lu, L.-C., Yang, C., Lin, C., & Chang, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210656 · Cited by 12
Ruggenenti, P. L., Cortinovis, M., Parvanova, A. I., Trillini, M., Iliev, I. P., Bossi, A. C., Belviso, A., Aparicio, M., Trevisan, R., Rota, S., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003691 · Cited by 12
Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 16
Emerging drugs for chronic kidney disease
Stefoni, S., Cianciolo, G., Baraldi, O., Iorio, M., & Angelini, M. L. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.900044 · Cited by 12
Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 12
Pharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 14
Sex differences in hypertension and other cardiovascular diseases
Delles, C., & Currie, G. E. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001655 · Cited by 12
Protein restriction: a revisited old strategy with new opportunities?
Locatelli, F., & Vecchio, L. D. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu218 · Cited by 11
Blood Pressure Control and Cardiovascular/Renal Outcomes
Dojki, F. K., & Bakris, G. L. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.008 · Cited by 14
Zhou, P., Wang, N., Lu, S., Xiong, J., Zhang, Y., Jiang, Q., Qian, Q., Zhou, Q., Liu, J., & Chen, S. (2024) · Translational research · doi:10.1016/j.trsl.2024.09.005 · Cited by 13
Huang, N., Xu, Y., Liu, C., Liu, Y., Fan, Y., Li, Z., Zhang, D., Mao, H., & Chen, W. (2025) · Drugs · doi:10.1007/s40265-025-02198-6 · Cited by 12
Mann, J. F. E., Rossing, P. R., Więcek, A., Rosivall, L., Mark, P. B., & Mayer, G. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv120 · Cited by 11
Hipertensión arterial en la enfermedad renal crónica
Arroyo, D., Quiroga, B., & de la Fuente, G. D. A. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.06.003 · Cited by 16
The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease
Shen, W., Alshehri, M. A., Desale, S. Y., & Wilcox, C. S. (2021) · American Journal of Nephrology · doi:10.1159/000515809 · Cited by 11
Blood Pressure Control in Patients with Diabetic Kidney Disease
Kim, Y., Kim, W. B., Kim, J.-K., Moon, J.-Y., Park, S., Park, C. W., Park, H. S., Song, S. H., Yoo, T., Lee, S.-Y., et al. (2022) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2022.20.2.39 · Cited by 13
Management of Hypertension in Diabetic Kidney Disease
Colbert, G. B., Elrggal, M. E., Gaddy, A. R., Madariaga, H. M., & Lerma, E. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216868 · Cited by 12
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis
Matsushita, K., Yang, H.-C., Mysore, M. M., Zhong, J., Shyr, Y., Ma, L.-J., & Fogo, A. B. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.42 · Cited by 11
Bailey, J., Tata, A. L., Waite, L. H., & D’Angelo, R. G. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.ckd_overview · Cited by 11
LINK‑A lncRNA activates HIF1α signaling and inhibits podocyte cell apoptosis in diabetic nephropathy
Yang, J., Li, L., Hong, S., Zhou, Z., & Fan, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7542 · Cited by 13
Chábová, V. Č., & Červenka, L. (2017) · Physiological Research · doi:10.33549/physiolres.933607 · Cited by 12
Mei, M., Zhou, Z., Zhang, Q., Chen, Y., Zhao, H., & Shen, B. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000513119 · Cited by 11
ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease
Fried, L. F., Petruski‐Ivleva, N., Folkerts, K., Schmedt, N., Velentgas, P., & Kovesdy, C. P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88806 · Cited by 12
Self-citationAlicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00003-3 · Cited by 12
Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD
Fried, L. F., & Lewis, J. B. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01610215 · Cited by 11
Self-citationSnyder, S., & John, J. S. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.010 · Cited by 14
ACE inhibitor and ARB therapy: Practical recommendations
Rincon-Choles, H. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.19016 · Cited by 11
Hirsch, D. S., Lau, B., Kushwaha, V. V., & Yong, K. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406181 · Cited by 15
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis
Huang, Z., Zhang, H., Luo, Y., Wei, C., Zhao, Y., Huang, Y., Zhang, L., Chen, W., He, L., Liu, H., et al. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1919528 · Cited by 11
Gnudi, L. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104159 · Cited by 12
Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona
Egocheaga, M. I., Hernández, Y. D., & Otero, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102018 · Cited by 11
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Treatment of Hypertension in Older Persons: What Is the Evidence?
Morley, J. E. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0171-7 · Cited by 11
Velde‐Keyzer, C. A. T., de Jong, M. A., van Breda, G. F., Vervloet, M. G., Laverman, G. D., Hemmelder, M. H., Janssen, W. M. T., Heerspink, H. J. L., Navis, G. J., & de Borst, M. H. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv033 · Cited by 11
Concepts in Diabetic Nephropathy: From Pathophysiology to Treatment
Kinaan, M., Yau, H., Martinez, S., & Kar, P. M. (2017) · Journal of Renal and Hepatic Disorders · doi:10.15586/jrenhep.2017.17 · Cited by 12
Hirai, T., Yamaga, R., Fujita, A., & Itoh, T. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12720 · Cited by 12
Charnaya, O., & Seifert, M. E. (2020) · Pediatric Transplantation · doi:10.1111/petr.13811 · Cited by 10
A narrative review of new treatment options for chronic kidney disease in type 2 diabetes
Persson, F., Borg, R., & Rossing, P. R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4841 · Cited by 13
Sallam, A.-A. M., Salem, M., Abdel-Aleem, E., & EL-Mesallamy, H. O. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1517-6643 · Cited by 10
Hypertension and Diabetic Nephropathy
Skov, J., Christiansen, J. S., & Poulsen, P. L. (2016) · Endocrine development · doi:10.1159/000439393 · Cited by 12
Allen, C., & Donegan, K. L. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4219 · Cited by 10
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
Novel approaches for treating hypertension
Freeman, A. J., Vinh, A., & Widdop, R. E. (2017) · F1000Research · doi:10.12688/f1000research.10117.1 · Cited by 12
Nakamoto, H., Yu, X., Kim, S., Origasa, H., Zheng, H., Chen, J., Joo, K. W., Sritippayawan, S., Chen, Q., Chen, H., et al. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12840 · Cited by 10
A Quest — Halting the Progression of Autosomal Dominant Polycystic Kidney Disease
Ellison, D. H., & Ingelfinger, J. R. (2014) · New England Journal of Medicine · doi:10.1056/nejme1412586 · Cited by 10
SGLT2 inhibitors: new kids on the block to control hyperkalemia
Gabai, P., & Fouque, D. P. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad026 · Cited by 9
Shenkang protects renal function in diabetic rats by preserving nephrin expression
Qu, Z., Wang, B., Jin, Y., Xiao, Q., Zhao, Y. L., Zhao, D., & Yang, L. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04078-6 · Cited by 10
Morales, J., & Palmer, B. F. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2316572 · Cited by 9
Aldosterone synthase inhibition in chronic kidney disease
Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001089 · Cited by 10
Microbubbles and Ultrasound: Therapeutic Applications in Diabetic Nephropathy
Cao, W. J., Matkar, P. N., Chen, H. H., Mofid, A., & Leong-Poi, H. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22536-4_17 · Cited by 10
Capítulo 10 - Hipertensão na Criança e no Adolescente
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160160 · Cited by 10
Huang, Y., Fried, L. F., Kyriakides, T. C., Johnson, G. R., Chiu, S., Mcdonald, L., & Zhang, J. H. (2018) · Clinical Trials · doi:10.1177/1740774518813121 · Cited by 9
Self-citationManagement of proteinuria: blockade of the renin-angiotensin-aldosterone system
Athavale, A., & Roberts, D. M. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.021 · Cited by 9
The future of Diabetic Kidney Disease management: reducing the unmet need
de Zeeuw, D. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00820-2 · Cited by 10
COVID-19 and Diabetic Nephropathy
Maremonti, F., Locke, S., Tonnus, W., Beer, K., Brucker, A. M., Gonzalez, N. Z., Latk, M., Belavgeni, A., Hoppenz, P., Hugo, C., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1819-4822 · Cited by 9
Rashikh, M. A., Alruways, A. F., Alotaibi, H. B., Alotaibi, N., Almarshad, F., Alsaab, S. O., & Alotaibi, G. (2023) · Cureus · doi:10.7759/cureus.34965 · Cited by 10
Hirota, K., Yamashita, A., Abe, E., Yamaji, T., Azushima, K., Tanaka, S., Taguchi, S., Tsukamoto, S., Wakui, H., & Tamura, K. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105478 · Cited by 9
Patient Engagement and Informed Decision Making Regarding Medical Imaging
Tapp, H., McWilliams, A. D., & Dulin, M. (2014) · North Carolina Medical Journal · doi:10.18043/ncm.75.2.114 · Cited by 9
Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients
Isaacs, A. N., & Vincent, A. H. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12361 · Cited by 9
Nodular glomerulosclerosis and renin angiotensin system in Chinese patients with type 2 diabetes
Wang, M., Zhang, X., Song, X.-N., Zou, X., Wu, W., Wang, Y., Lin, B., Li, R., Hu, F., & Zhao, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.008 · Cited by 9
Dual renin–angiotensin system blockade for nephroprotection
Ruggenenti, P. L. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.02.006 · Cited by 9
Patney, V., Chaudhary, K. R., & Whaley‐Connell, A. T. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.002 · Cited by 9
Satheeshkumar, A., Peña, C., & NUGENT, K. M. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000364 · Cited by 9
Singh, A. K., & Singh, R. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i7.471 · Cited by 13
van Blijderveen, J. C., Straus, S. M. J. M., de Ridder, M. A., Stricker, B. H. C., Sturkenboom, M., & Verhamme, K. M. C. (2014) · Drug Safety · doi:10.1007/s40264-014-0160-0 · Cited by 9
Rajagopalan, S., Alaiti, M. A., Broadwater, K., Goud, A., Gaztañaga, J., Connelly, K. A., Fares, A., Shirazian, S., Kreatsoulas, C., Farkouh, M. E., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22718 · Cited by 10
Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology
Tang, S. C. W., Wong, A. K., & Mak, S. (2019) · Nephrology · doi:10.1111/nep.13500 · Cited by 9
Hiß, M., & Kielstein, J. T. (2014) · Springer eBooks · doi:10.1007/978-3-642-54859-8_30 · Cited by 9
Fravel, M. A., Meaney, C. J., & Noureddine, L. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01265-1 · Cited by 9
Goupil, R., Tsuyuki, R. T., Santesso, N. A., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A. C., Campbell, N. R. C., et al. (2025) · Canadian Family Physician · doi:10.46747/cfp.20250616001 · Cited by 9
Not all proteinuria is created equal
Beenken, A., Barasch, J. M., & Gharavi, A. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci133250 · Cited by 8
Geng, Y., Dong, Z., Wang, Y., Zhang, P., Tang, J., Li, P., Ren-he, L., Liu, Y., & Liu, W. J. (2023) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-22-00020 · Cited by 8
Momuat, A. G. F., & Annisaa’, E. (2023) · Generics Journal of Research in Pharmacy · doi:10.14710/genres.v3i1.17210 · Cited by 8
Chen, C., Lin, M. C., Xie, X.-Y., Lin, C., Yang, C., Wu, P.-C., Liu, D.-H., Wu, C., & Lin, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010329 · Cited by 8
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider
Brady, B. M., Suffoletto, J.-A., Sankary, R., & Chertow, G. M. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02638-4 · Cited by 10
Morales, E., Martin, W. P., Bevc, S., Jenssen, T. G., Miglinas, M., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf069 · Cited by 8
Optimizing Care for Canadians with Diabetic Nephropathy in 2015
Lloyd, A., & Komenda, P. V. J. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.11.001 · Cited by 11
Update in Hypertension Therapy
Mankin, L. A. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.005 · Cited by 9
Chang, S., Lo, C., Zhao, X. C., Liao, M.-C., Chénier, I., Bouley, R., Ingelfinger, J. R., Chan, J. S. D., & Zhang, S. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316668737 · Cited by 8
Mavrakanas, T. A., & Lipman, M. L. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.006 · Cited by 9
Donderski, R. Ł., Bednarski, R., & Manitius, J. (2020) · Arterial Hypertension · doi:10.5603/ah.a2020.0007 · Cited by 10
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.